标题:Recent advances in the discovery of potent and selective HDAC6 inhibitors
作者:Wang, Xiu-Xiu; Wan, Ren-Zhong; Liu, Zhao-Peng
作者机构:[Wang, Xiu-Xiu; Liu, Zhao-Peng] Shandong Univ, Inst Med Chem, Sch Pharmaceut Sci, Key Lab Chem Biol,Minist Educ, Jinan 250012, Shandong, Peoples R Chi 更多
通讯作者:Liu, ZP;Wan, RZ
通讯作者地址:[Liu, ZP]Shandong Univ, Inst Med Chem, Sch Pharmaceut Sci, Key Lab Chem Biol,Minist Educ, Jinan 250012, Shandong, Peoples R China;[Wan, RZ]Shandong Ag 更多
来源:EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
出版年:2018
卷:143
页码:1406-1418
DOI:10.1016/j.ejmech.2017.10.040
关键词:HDAC6; HDAC6 inhibitors; Zinc binding groups; Hydroxamic acids; Sulfur; containing ZBGs
摘要:Histone deacetylase HDAC6, a member of the class Ilb HDAC family, is unique among HDAC enzymes in having two active catalytic domains, and has unique physiological function. In addition to the modification of histone, HDAC6 targets specific substrates including a-tubulin and HSP90, and are involved in protein trafficking and degradation, cell shape and migration. Selective HDAC6 inhibitors are an emerging class of pharmaceuticals due to the involvement of HDAC6 in different pathways related to neurodegenerative diseases, cancer, and immunology. Therefore, extensive investigations have been made in the discovery of selective HDAC6 inhibitors. Based on their different zinc binding groups (ZBGs), in this review, HDAC6 inhibitors are grouped as hydroxamic acids, a sulfur containing ZBG based derivatives and other ZBG-derived compounds, and their enzymatic inhibitory activity, selectivity and other biological activities are introduced and summarized. (C) 2017 Elsevier Masson SAS. All rights reserved.
收录类别:SCOPUS;SCIE
WOS核心被引频次:4
Scopus被引频次:3
资源类型:期刊论文
原文链接:https://www.scopus.com/inward/record.uri?eid=2-s2.0-85033573917&doi=10.1016%2fj.ejmech.2017.10.040&partnerID=40&md5=89c63a52791c006a62aa292d0d36d54e
TOP